Irene Agodoa, MD, on Addressing GVHD Risks in Treating Hematologic Malignancies

Video

The senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.

“Graft-versus-host disease (GVHD) is 1 of the serious complications that we're looking to address with the Orca-T product. And because we have defined compositions of cells, really purified T regulatory cells, stem cells and conventional T cells, we've seen really great results in being able to mitigate and significantly reduce the amount of GVHD that we see in patients that receive Orca-T. So, that's really encouraging.”

The phase 3 Precision-T clinical trial (NCT05316701) is now evaluating Orca-T, Orca Bio’s allogeneic cell therapy, in participants with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and high-risk myelodysplastic syndromes (MDS). The trial is comparing the safety and efficacy of Orca-T against standard of care allogeneic hematopoietic stem cell transplant (allo-HSCT).

Orca Bio has developed Orca-T with the goal of mitigating GVHD and other transplant-related adverse events that are current possible drawbacks to standard allo-HSCT. To this end, Precision-T, which has now begun dosing in centers around the US, will primarily be assessing the incidence of GVHD.

CGTLive spoke with Irene Agodoa, MD, senior vice president and head, medical affairs, Orca Bio, to learn more about Orca-T's advantages in mitigating GVHD. She also discussed the impact of GVHD in patients that receive allo-HSCT.

REFERENCE
Orca Bio announces the Precision-T phase 3 study is open and enrolling patients at transplant centers across the US. News release. Orca Bio. August 2, 2022. https://orcabio.com/2022-08-02/
Related Videos
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
Subhash Tripathi, PhD, on Developing Safe, Specific Engineered Treg Cell Therapy
© 2024 MJH Life Sciences

All rights reserved.